614 related articles for article (PubMed ID: 8941874)
1. Lysis of syngeneic tumor B cells by autoreactive cytotoxic T lymphocytes specific for a CD19 antigen-derived synthetic peptide.
Hooijberg E; Visseren MJ; van den Berk PC; Jellema AP; Romeijn P; Sein JJ; van der Voort EI; Hekman A; Ossendorp F; Melief CJ
J Immunother Emphasis Tumor Immunol; 1996 Sep; 19(5):346-56. PubMed ID: 8941874
[TBL] [Abstract][Full Text] [Related]
2. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies.
Bae J; Martinson JA; Klingemann HG
Clin Cancer Res; 2005 Feb; 11(4):1629-38. PubMed ID: 15746068
[TBL] [Abstract][Full Text] [Related]
3. Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity.
Feltkamp MC; Vierboom MP; Kast WM; Melief CJ
Mol Immunol; 1994 Dec; 31(18):1391-401. PubMed ID: 7823965
[TBL] [Abstract][Full Text] [Related]
4. A self-reactive class I-restricted T-cell response of H-2b mice to determinants of the V beta 8.2 domain of the T-cell receptor for antigen.
Kuhröber A; Schirmbeck R; Reimann J
Immunology; 1994 Dec; 83(4):532-9. PubMed ID: 7533132
[TBL] [Abstract][Full Text] [Related]
5. Presentation of a horse cytochrome c peptide by multiple H-2b class I major histocompatibility complex (MHC) molecules to C57BL/6- and bm1-derived cytotoxic T lymphocytes: presence of a single MHC anchor residue may confer efficient peptide-specific CTL recognition.
Sheil JM; Schell TD; Shepherd SE; Klimo GF; Kioschos JM; Paterson Y
Eur J Immunol; 1994 Sep; 24(9):2141-9. PubMed ID: 7522163
[TBL] [Abstract][Full Text] [Related]
6. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.
Abrams SI; Stanziale SF; Lunin SD; Zaremba S; Schlom J
Eur J Immunol; 1996 Feb; 26(2):435-43. PubMed ID: 8617315
[TBL] [Abstract][Full Text] [Related]
7. Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization.
Feltkamp MC; Vierboom MP; Toes RE; Ossendorp F; ter Schegget J; Melief CJ; Kast WM
Immunol Lett; 1995; 47(1-2):1-8. PubMed ID: 8537084
[TBL] [Abstract][Full Text] [Related]
8. In vivo treatment with a MHC class I-restricted blocking peptide can prevent virus-induced autoimmune diabetes.
von Herrath MG; Coon B; Lewicki H; Mazarguil H; Gairin JE; Oldstone MB
J Immunol; 1998 Nov; 161(9):5087-96. PubMed ID: 9794447
[TBL] [Abstract][Full Text] [Related]
9. Interaction of in vitro- and in vivo-generated cytotoxic T cells with SV40 T antigen: analysis with synthetic peptides.
Alsheikhly AR
Scand J Immunol; 1994 May; 39(5):467-79. PubMed ID: 8191222
[TBL] [Abstract][Full Text] [Related]
10. Identification of MHC class I H-2 Kb/Db-restricted immunogenic peptides derived from retinal proteins.
Wang M; Bai F; Pries M; Buus S; Prause JU; Nissen MH
Invest Ophthalmol Vis Sci; 2006 Sep; 47(9):3939-45. PubMed ID: 16936108
[TBL] [Abstract][Full Text] [Related]
11. Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes.
Blake J; Johnston JV; Hellström KE; Marquardt H; Chen L
J Exp Med; 1996 Jul; 184(1):121-30. PubMed ID: 8691125
[TBL] [Abstract][Full Text] [Related]
12. Differential binding of a minor histocompatibility antigen peptide to H-2 class I molecules correlates with immune responsiveness.
Wettstein PJ; van Bleek GM; Nathenson SG
J Immunol; 1993 Apr; 150(7):2753-60. PubMed ID: 7681080
[TBL] [Abstract][Full Text] [Related]
13. The immunodominant, Ld-restricted T cell response to hepatitis B surface antigen (HBsAg) efficiently suppresses T cell priming to multiple Dd-, Kd-, and Kb-restricted HBsAg epitopes.
Schirmbeck R; Stober D; El-Kholy S; Riedl P; Reimann J
J Immunol; 2002 Jun; 168(12):6253-62. PubMed ID: 12055239
[TBL] [Abstract][Full Text] [Related]
14. Correlation between CD8 dependency and determinant density using peptide-induced, Ld-restricted cytotoxic T lymphocytes.
Alexander MA; Damico CA; Wieties KM; Hansen TH; Connolly JM
J Exp Med; 1991 Apr; 173(4):849-58. PubMed ID: 1901079
[TBL] [Abstract][Full Text] [Related]
15. Tetramer-blocking assay for defining antigen-specific cytotoxic T lymphocytes using peptide-MHC tetramer.
Yokouchi H; Chamoto K; Wakita D; Noguchi D; Yamazaki K; Dosaka-Akita H; Nishimura M; Ikeda H; Nishimura T
Cancer Sci; 2006 Feb; 97(2):148-54. PubMed ID: 16441426
[TBL] [Abstract][Full Text] [Related]
16. Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies.
Grube M; Rezvani K; Wiestner A; Fujiwara H; Sconocchia G; Melenhorst JJ; Hensel N; Marti GE; Kwak LW; Wilson W; Barrett JA
Clin Cancer Res; 2004 Feb; 10(3):1047-56. PubMed ID: 14871984
[TBL] [Abstract][Full Text] [Related]
17. Recognition of H-2Kb mutant target cells by Moloney virus-specific cytotoxic T lymphocytes from bm13 (H-2Db mutant) mice. I. Full recognition of Kbm11 by Kb-restricted CTL.
Stukart MJ; Boes J; Melief CJ
J Immunol; 1984 Jul; 133(1):24-7. PubMed ID: 6202782
[TBL] [Abstract][Full Text] [Related]
18. Mapping of epitopes recognized by alloreactive cytotoxic T lymphocytes using inhibition by MHC peptides.
Heath WR; Vitiello A; Sherman LA
J Immunol; 1989 Sep; 143(5):1441-6. PubMed ID: 2474598
[TBL] [Abstract][Full Text] [Related]
19. Alloreactive cytotoxic T lymphocytes generated in the presence of viral-derived peptides show exquisite peptide and MHC specificity.
Alexander-Miller MA; Burke K; Koszinowski UH; Hansen TH; Connolly JM
J Immunol; 1993 Jul; 151(1):1-10. PubMed ID: 8392095
[TBL] [Abstract][Full Text] [Related]
20. Recognition of breast cancer-associated peptides by tumor-reactive, HLA-class I restricted allogeneic cytotoxic T lymphocytes.
Nguyen T; Naziruddin B; Dintzis S; Doherty GM; Mohanakumar T
Int J Cancer; 1999 May; 81(4):607-15. PubMed ID: 10225452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
